Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery

Molecular Oncology

Volumn 10, Issue 8, 2016, Pages 1221-1231

  Denis, Jérôme Alexandre ^a,b,c   Patroni, Alexia ^b   Guillerm, Erell ^a,b   Pépin, Dominique ^b   Benali Furet, Naoual ^d   Wechsler, Janine ^d   Manceau, Gilles ^a,b   Bernard, Maguy ^b   Coulet, Florence ^a,b   Larsen, Annette K ^c   Karoui, Mehdi ^a,b   Lacorte, Jean Marc ^a,b,e  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^d ScreenCell SA   (France)

^e INSERM   (France)

Author keywords

Circulating tumor cells; Colorectal cancer; Digital PCR; KRAS; Liquid biopsy

Indexed keywords

DNA; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CELL ISOLATION; CELL MUTANT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CODON; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DNA MICROARRAY KIT; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; VERY ELDERLY; COLORECTAL NEOPLASMS; GENE DOSAGE; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE DOSAGE; GENOTYPE; HUMANS; MALE; MUTATION; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS); REPRODUCIBILITY OF RESULTS;

EID: 84993969514     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.05.009     Document Type: Article

References (53)

1. Alix-Panabieres, C., Pantel, K., Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 14 (2014), 57–62.
2. Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S.D., Chang, D.D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008), 1626–1634.
3. Andree, K.C., van Dalum, G., Terstappen, L.W., Challenges in circulating tumor cell detection by the CellSearch system. Mol. Oncol. 10:3 (2016), 395–407.
4. Barriere, G., Fici, P., Gallerani, G., Fabbri, F., Zoli, W., Rigaud, M., Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann. Transl Med., 2, 2014, 109.
5. Barriere, G., Tartary, M., Rigaud, M., Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol., 2012, 2014, 382010.
6. Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B.R., Wang, H., Luber, B., Alani, R.M., Antonarakis, E.S., Azad, N.S., Bardelli, A., Brem, H., Cameron, J.L., Lee, C.C., Fecher, L.A., Gallia, G.L., Gibbs, P., Le, D., Giuntoli, R.L., Goggins, M., Hogarty, M.D., Holdhoff, M., Hong, S.M., Jiao, Y., Juhl, H.H., Kim, J.J., Siravegna, G., Laheru, D.A., Lauricella, C., Lim, M., Lipson, E.J., Marie, S.K., Netto, G.J., Oliner, K.S., Olivi, A., Olsson, L., Riggins, G.J., Sartore-Bianchi, A., Schmidt, K., Shih l, M., Oba-Shinjo, S.M., Siena, S., Theodorescu, D., Tie, J., Harkins, T.T., Veronese, S., Wang, T.L., Weingart, J.D., Wolfgang, C.L., Wood, L.D., Xing, D., Hruban, R.H., Wu, J., Allen, P.J., Schmidt, C.M., Choti, M.A., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Papadopoulos, N., Diaz, L.A. Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014 224ra224.
7. Bird, N.C., Mangnall, D., Majeed, A.W., Biology of colorectal liver metastases: a review. J. Surg. Oncol. 94 (2006), 68–80.
8. Buim, M.E., Fanelli, M.F., Souza, V.S., Romero, J., Abdallah, E.A., Mello, C.A., Alves, V., Ocea, L.M., Mingues, N.B., Barbosa, P.N., Tyng, C.J., Chojniak, R., Chinen, L.T., Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol. Ther. 16 (2015), 1289–1295.
9. Cai, X., Janku, F., Zhan, Q., Fan, J.B., Accessing genetic information with liquid biopsies. Trends Genet. 31 (2015), 564–575.
10. Cao, H., Xu, E., Liu, H., Wan, L., Lai, M., Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol. Res. Pract. 211 (2015), 557–569.
11. Chisholm, R.H., Lorenzi, T., Lorz, A., Larsen, A.K., de Almeida, L.N., Escargueil, A., Clairambault, J., Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. Cancer Res. 75 (2015), 930–939.
12. Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M., Mitchell, E., Miller, M.C., Doyle, G.V., Tissing, H., Terstappen, L.W., Meropol, N.J., Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008), 3213–3221.
13. Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M.A., Mitchell, E., Miller, M.C., Doyle, G.V., Tissing, H., Terstappen, L.W., Meropol, N.J., Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 20 (2009), 1223–1229.
14. Desitter, I., Guerrouahen, B.S., Benali-Furet, N., Wechsler, J., Janne, P.A., Kuang, Y., Yanagita, M., Wang, L., Berkowitz, J.A., Distel, R.J., Cayre, Y.E., A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 31 (2011), 427–441.
15. Earl, J., Garcia-Nieto, S., Martinez-Avila, J.C., Montans, J., Sanjuanbenito, A., Rodriguez-Garrote, M., Lisa, E., Mendia, E., Lobo, E., Malats, N., Carrato, A., Guillen-Ponce, C., Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine. 2014.
16. Franklin, W.A., Haney, J., Sugita, M., Bemis, L., Jimeno, A., Messersmith, W.A., KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J. Mol. Diagn. 12 (2010), 43–50.
17. Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A.M., Mauermann, O., Izbicki, J.R., Pantel, K., Riethdorf, S., Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59 (2013), 252–260.
18. Gingras, I., Salgado, R., Ignatiadis, M., Liquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies?. Curr. Opin. Oncol. 27 (2015), 560–567.
19. Guttery, D.S., Page, K., Hills, A., Woodley, L., Marchese, S.D., Rghebi, B., Hastings, R.K., Luo, J., Pringle, J.H., Stebbing, J., Coombes, R.C., Ali, S., Shaw, J.A., Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 61 (2015), 974–982 pancreatic cancer. BMC Cancer 15, 797.
20. Gutierrez, C., Rodriguez, J., Patino-Garcia, A., Garcia-Foncillas, J., Salgado, J., Mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. Oncol Lett. 6 (2013), 1343–1345.
21. Hardingham, J.E., Grover, P., Winter, M., Hewett, P.J., Price, T.J., Thierry, B., Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress. Mol. Med. 21:Suppl. 1 (2015), S25–S31.
22. Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (2015), 112–123.
23. Hindson, B.J., Ness, K.D., Masquelier, D.A., Belgrader, P., Heredia, N.J., Makarewicz, A.J., Bright, I.J., Lucero, M.Y., Hiddessen, A.L., Legler, T.C., Kitano, T.K., Hodel, M.R., Petersen, J.F., Wyatt, P.W., Steenblock, E.R., Shah, P.H., Bousse, L.J., Troup, C.B., Mellen, J.C., Wittmann, D.K., Erndt, N.G., Cauley, T.H., Koehler, R.T., So, A.P., Dube, S., Rose, K.A., Montesclaros, L., Wang, S., Stumbo, D.P., Hodges, S.P., Romine, S., Milanovich, F.P., White, H.E., Regan, J.F., Karlin-Neumann, G.A., Hindson, C.M., Saxonov, S., Colston, B.W., High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83 (2011), 8604–8610.
24. Hindson, C.M., Chevillet, J.R., Briggs, H.A., Gallichotte, E.N., Ruf, I.K., Hindson, B.J., Vessella, R.L., Tewari, M., Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10 (2013), 1003–1005.
25. Hudecova, I., Digital PCR analysis of circulating nucleic acids. Clin. Biochem. 48 (2015), 948–956.
26. Joosse, S.A., Gorges, T.M., Pantel, K., Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol. Med. 7 (2014), 1–11.
27. Laurent-Puig, P., Pekin, D., Normand, C., Kotsopoulos, S.K., Nizard, P., Perez-Toralla, K., Rowell, R., Olson, J., Srinivasan, P., Le Corre, D., Hor, T., El Harrak, Z., Li, X., Link, D.R., Bouche, O., Emile, J.F., Landi, B., Boige, V., Hutchison, J.B., Taly, V., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 21 (2015), 1087–1097.
28. Lianidou, E.S., Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?. Clin. Chem. 60 (2014), 1249–1251.
29. Lianidou, E.S., Markou, A., Strati, A., The role of CTCs as tumor biomarkers. Adv. Exp. Med. Biol. 867 (2015), 341–367.
30. Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F., Cote, J.F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F., Laurent-Puig, P., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66 (2006), 3992–3995.
31. Lim, L.S., Hu, M., Huang, M.C., Cheong, W.C., Gan, A.T., Looi, X.L., Leong, S.M., Koay, E.S., Li, M.H., Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip 12 (2012), 4388–4396.
32. Lim, S.H., Becker, T.M., Chua, W., Caixeiro, N.J., Ng, W.L., Kienzle, N., Tognela, A., Lumba, S., Rasko, J.E., de Souza, P., Spring, K.J., Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett. 346 (2014), 24–33.
33. Lyberopoulou, A., Aravantinos, G., Efstathopoulos, E.P., Nikiteas, N., Bouziotis, P., Isaakidou, A., Papalois, A., Marinos, E., Gazouli, M., Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One, 10, 2015 e0123902.
34. Ma, M., Zhu, H., Zhang, C., Sun, X., Gao, X., Chen, G., “Liquid biopsy”-ctDNA detection with great potential and challenges. Ann. Transl. Med., 3, 2015, 235.
35. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., Bardelli, A., Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4 (2014), 1269–1280.
36. Mohamed Suhaimi, N.A., Foong, Y.M., Lee, D.Y., Phyo, W.M., Cima, I., Lee, E.X., Goh, W.L., Lim, W.Y., Chia, K.S., Kong, S.L., Gong, M., Lim, B., Hillmer, A.M., Koh, P.K., Ying, J.Y., Tan, M.H., Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol. Oncol. 9 (2015), 850–860.
37. Mostert, B., Jiang, Y., Sieuwerts, A.M., Wang, H., Bolt-de Vries, J., Biermann, K., Kraan, J., Lalmahomed, Z., van Galen, A., de Weerd, V., van der Spoel, P., Ramirez-Moreno, R., Verhoef, C., Ijzermans, J.N., Wang, Y., Gratama, J.W., Foekens, J.A., Sleijfer, S., Martens, J.W., KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int. J. Cancer 133 (2013), 130–141.
38. Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
39. Pantel, K., Alix-Panabieres, C., Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 73 (2013), 6384–6388.
40. Pantel, K., Speicher, M.R., The biology of circulating tumor cells. Oncogene 35:10 (2015), 1216–1224.
41. Peeters, M., Douillard, J.Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., Wiezorek, J., Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 31 (2013), 759–765.
42. Raimondi, C., Nicolazzo, C., Gradilone, A., Giannini, G., De Falco, E., Chimenti, I., Varriale, E., Hauch, S., Plappert, L., Cortesi, E., Gazzaniga, P., Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol. Ther. 15 (2014), 496–503.
43. Shen, T., Pajaro-Van de Stadt, S.H., Yeat, N.C., Lin, J.C., Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front. Genet., 6, 2015, 215.
44. Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R., Nobili, S., Mini, E., Pazzagli, M., Orlando, C., High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol. 130 (2008), 247–253.
45. Taly, V., Pekin, D., Benhaim, L., Kotsopoulos, S.K., Le Corre, D., Li, X., Atochin, I., Link, D.R., Griffiths, A.D., Pallier, K., Blons, H., Bouche, O., Landi, B., Hutchison, J.B., Laurent-Puig, P., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59:12 (2013), 1722–1731, 10.1373/clinchem.2013.206359.
46. Therkildsen, C., Bergmann, T.K., Henrichsen-Schnack, T., Ladelund, S., Nilbert, M., The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 53 (2014), 852–864.
47. Thierry, A.R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., Del Rio, M., Lamy, P.J., Bibeau, F., Nouaille, M., Loriot, V., Jarrousse, A.S., Molina, F., Mathonnet, M., Pezet, D., Ychou, M., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20 (2014), 430–435.
48. Torino, F., Bonmassar, E., Bonmassar, L., De Vecchis, L., Barnabei, A., Zuppi, C., Capoluongo, E., Aquino, A., Circulating tumor cells in colorectal cancer patients. Cancer Treat. Rev. 39 (2013), 759–772.
49. Tsiatis, A.C., Norris-Kirby, A., Rich, R.G., Hafez, M.J., Gocke, C.D., Eshleman, J.R., Murphy, K.M., Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J. Mol. Diagn. 12 (2010), 425–432.
50. Williams, A., Balic, M., Datar, R., Cote, R., Size-based enrichment technologies for CTC detection and characterization. Recent Results Cancer Res. 195 (2012), 87–95.
51. Yang, M.H., Imrali, A., Heeschen, C., Circulating cancer stem cells: the importance to select. Chin J. Cancer Res. 27 (2015), 437–449.
52. Yu, M., Bardia, A., Wittner, B.S., Stott, S.L., Smas, M.E., Ting, D.T., Isakoff, S.J., Ciciliano, J.C., Wells, M.N., Shah, A.M., Concannon, K.F., Donaldson, M.C., Sequist, L.V., Brachtel, E., Sgroi, D., Baselga, J., Ramaswamy, S., Toner, M., Haber, D.A., Maheswaran, S., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
53. Zuo, Z., Chen, S.S., Chandra, P.K., Galbincea, J.M., Soape, M., Doan, S., Barkoh, B.A., Koeppen, H., Medeiros, L.J., Luthra, R., Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod. Pathol. 22 (2009), 1023–1031.